Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies
Issued Date
2023-04-01
Resource Type
ISSN
10983015
eISSN
15244733
Scopus ID
2-s2.0-85143866144
Pubmed ID
36328324
Journal Title
Value in Health
Volume
26
Issue
4
Start Page
598
End Page
611
Rights Holder(s)
SCOPUS
Bibliographic Citation
Value in Health Vol.26 No.4 (2023) , 598-611
Suggested Citation
Syeed M.S., Ghule P., Le L.M., Veettil S.K., Horn E.K., Perdrizet J., Wasserman M., Thakkinstian A., Chaiyakunapruk N. Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies. Value in Health Vol.26 No.4 (2023) , 598-611. 611. doi:10.1016/j.jval.2022.10.006 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82348
Title
Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies
Other Contributor(s)
Abstract
Objectives: Pneumococcal conjugate vaccines (PCVs) have significantly reduced disease burden caused by Streptococcus pneumoniae, a leading cause of childhood morbidity and mortality globally. This systematic review and meta-analysis aimed to assess the incremental net benefit (INB) of the 13-valent PCV (PCV13) and 10-valent PCV (PCV10) in children. Methods: We performed a comprehensive search in several databases published before May 2022. Studies were included if they were cost-effectiveness or cost-utility analyses of PCV13 or PCV10 compared with no vaccination or with each other in children. Various monetary units were converted to purchasing power parity, adjusted to 2021 US dollars. The INBs were calculated and then pooled across studies stratified by country income level, perspective, and consideration of herd effects, using a random-effect model. Results: Seventy studies were included. When herd effects were considered, PCV13 was cost-effective compared with PCV10 from the payer perspective in both high-income countries (HICs) (INB, $103.94; 95% confidence interval, $75.28-$132.60) and low- and middle-income countries (LMICs) (INB, $53.49; 95% confidence interval, $30.42-$76.55) with statistical significance. These findings were robust across a series of sensitivity analyses. PCV13 was cost-effective compared with no vaccination across perspectives and consideration of herd effects in both HICs and LMICs, whereas findings were less consistent for PCV10. Conclusion: PCVs were generally cost-effective compared with no vaccination in HICs and LMICs. Our study found that PCV13 was cost-effective compared with PCV10 when herd effects were considered from the payer perspective in both HICs and LMICs. The results are sensitive to the consideration of herd effects.